{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:38:41Z","timestamp":1792417121977,"version":"4.4.0"},"reference-count":59,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed\/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. These data represent a proof of concept for the treatment of ccRCC and other CD70+ malignancies with CD70\u2212 targeted allogeneic CAR T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-24-0102","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T16:01:05Z","timestamp":1712505665000},"page":"1176-1189","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma"],"prefix":"10.1158","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K.","family":"Pal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-354X","authenticated-orcid":false,"given":"Ben","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, the Netherlands. 3"},{"name":"Leiden University Medical Center, Leiden, the Netherlands. 4"},{"name":"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-7308","authenticated-orcid":false,"given":"Michael E.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2701","authenticated-orcid":false,"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 7"},{"name":"Departments of Medicine and Immunology, University of Toronto, Toronto, Canada. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8060","authenticated-orcid":false,"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas. 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-0763","authenticated-orcid":false,"given":"Sebastian","family":"Klobuch","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, the Netherlands. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3615","authenticated-orcid":false,"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-297X","authenticated-orcid":false,"given":"Luis","family":"Meza","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8385-3547","authenticated-orcid":false,"given":"Mary-Lee","family":"Dequeant","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4522-1768","authenticated-orcid":false,"given":"Anna","family":"Ma","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7900-8736","authenticated-orcid":false,"given":"Qiuling Ally","family":"He","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-1081","authenticated-orcid":false,"given":"Leah M.","family":"Williams","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-9989","authenticated-orcid":false,"given":"Alissa","family":"Keegan","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-260X","authenticated-orcid":false,"given":"Ellen B.","family":"Gurary","sequence":"additional","affiliation":[{"name":"Formerly employed by CRISPR Therapeutics, Boston, Massachusetts. 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8825-4081","authenticated-orcid":false,"given":"Henia","family":"Dar","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8803-746X","authenticated-orcid":false,"given":"Sushant","family":"Karnik","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0611-3239","authenticated-orcid":false,"given":"Changan","family":"Guo","sequence":"additional","affiliation":[{"name":"Formerly employed by CRISPR Therapeutics, Boston, Massachusetts. 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-1268","authenticated-orcid":false,"given":"Heidi","family":"Heath","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-9185","authenticated-orcid":false,"given":"Rachel R.","family":"Yuen","sequence":"additional","affiliation":[{"name":"CRISPR Therapeutics, Boston, Massachusetts. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5349-6344","authenticated-orcid":false,"given":"Phuong K.","family":"Morrow","sequence":"additional","affiliation":[{"name":"Formerly employed by CRISPR Therapeutics, Boston, Massachusetts. 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6693-2025","authenticated-orcid":false,"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas. 9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"2026041309344247400_bib1","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/01.ju.0000158121.49085.ba","article-title":"CD70: a new tumor specific biomarker for renal cell carcinoma","volume":"173","author":"Junker","year":"2005","journal-title":"J Urol"},{"key":"2026041309344247400_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026041309344247400_bib3","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026041309344247400_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026041309344247400_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clgc.2016.10.008","article-title":"Impact of sequencing targeted therapies with high-dose interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial: PROCLAIM(SM)","volume":"15","author":"Clark","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2026041309344247400_bib6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma","volume":"338","author":"Negrier","year":"1998","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026041309344247400_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","article-title":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","volume":"108","author":"Auvray","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026041309344247400_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br J Cancer"},{"key":"2026041309344247400_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdw160","article-title":"Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma","volume":"27","author":"Nadal","year":"2016","journal-title":"Ann Oncol"},{"key":"2026041309344247400_bib15","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Claus","year":"2012","journal-title":"Cancer Res"},{"key":"2026041309344247400_bib16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers"},{"key":"2026041309344247400_bib17","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathol"},{"key":"2026041309344247400_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2567.1997.00134.x","article-title":"Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells","volume":"90","author":"Lens","year":"1997","journal-title":"Immunology"},{"key":"2026041309344247400_bib19","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.4049\/jimmunol.1700380","article-title":"T cell-derived CD70 delivers an immune checkpoint function in inflammatory T cell responses","volume":"199","author":"O\u2019Neill","year":"2017","journal-title":"J Immunol"},{"key":"2026041309344247400_bib20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1593\/neo.06451","article-title":"Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes","volume":"8","author":"Diegmann","year":"2006","journal-title":"Neoplasia"},{"key":"2026041309344247400_bib21","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","article-title":"Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies","volume":"23","author":"Aftimos","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026041309344247400_bib22","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cncr.31912","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma","volume":"125","author":"Pal","year":"2019","journal-title":"Cancer"},{"key":"2026041309344247400_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"key":"2026041309344247400_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-14-1425","article-title":"pVHL\/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma","volume":"21","author":"Ruf","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026041309344247400_bib25","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-12-0588","article-title":"Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res"},{"key":"2026041309344247400_bib26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00280-019-03796-4","article-title":"First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed\/refractory renal cell carcinoma","volume":"83","author":"Massard","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026041309344247400_bib27","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"key":"2026041309344247400_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","article-title":"First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70","volume":"77","author":"Owonikoko","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026041309344247400_bib29","doi-asserted-by":"crossref","first-page":"744823","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in Universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"2026041309344247400_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2026041309344247400_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"2026041309344247400_bib32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026041309344247400_bib33","first-page":"2021","article-title":"CD70 knockout: a novel approach to augment CAR-T cell function","volume-title":"Cancer Res","author":"Dequeant"},{"key":"2026041309344247400_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026041309344247400_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041309344247400_bib36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2026041309344247400_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9\u2013engineered CAR T cells in patients with relapsed\/ refractory (R\/R) T-cell malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"},{"key":"2026041309344247400_bib39","article-title":"KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR\/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors","author":"Wrocklage"},{"key":"2026041309344247400_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-ND02","article-title":"CTX112 and CTX131: next-generation CRISPR\/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors","volume":"83","author":"Terrett","year":"2023","journal-title":"Cancer Res"},{"key":"2026041309344247400_bib41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nature07924","article-title":"Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay","volume":"458","author":"Matsushita","year":"2009","journal-title":"Nature"},{"key":"2026041309344247400_bib42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2013.04.034","article-title":"Malt1-induced cleavage of Regnase-1 in CD4(+) helper T cells regulates immune activation","volume":"153","author":"Uehata","year":"2013","journal-title":"Cell"},{"key":"2026041309344247400_bib43","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41467-019-09028-w","article-title":"Regnase-1-mediated post-transcriptional regulation is essential for hematopoietic stem and progenitor cell homeostasis","volume":"10","author":"Kidoya","year":"2019","journal-title":"Nat Commun"},{"key":"2026041309344247400_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"2026041309344247400_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.coi.2016.01.011","article-title":"Regulation of T cell signaling and autoimmunity by RNA-binding proteins","volume":"39","author":"Jeltsch","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2026041309344247400_bib46","doi-asserted-by":"crossref","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-beta: from conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026041309344247400_bib47","doi-asserted-by":"crossref","first-page":"e133977","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"2026041309344247400_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"2026041309344247400_bib49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-beta signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"2026041309344247400_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.36401\/JIPO-22-7","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: the past and the future","volume":"6","author":"Srour","year":"2023","journal-title":"J Immunother Precis Oncol"},{"key":"2026041309344247400_bib51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"2026041309344247400_bib52","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041309344247400_bib53","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"2026041309344247400_bib54","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"2026041309344247400_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.091","article-title":"Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Dorff","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041309344247400_bib56","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"2026041309344247400_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026041309344247400_bib58","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026041309344247400_bib59","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-0102\/3440348\/cd-24-0102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/14\/7\/1176\/3481569\/cd-24-0102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/14\/7\/1176\/3481569\/cd-24-0102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:34:55Z","timestamp":1776087295000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/14\/7\/1176\/746117\/CD70-Targeted-Allogeneic-CAR-T-Cell-Therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4,4]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-24-0102","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.26134408.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416775.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134414.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416781.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134420.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134417.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416784.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134411.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416790.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416766.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416769.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134402.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416781","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416775","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416787","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134405.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416769","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134408","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134402","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134399","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416790","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416787.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416784","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416772","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416766","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26416772.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697423","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697435","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697447","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134399.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32697441","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.26134405","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.7309447.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.7309447","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}